Paediatricians and the pharmaceutical industry: an industry perspective of the challenges ahead.
The relationship between healthcare professionals and the pharmaceutical industry is under intense scrutiny. Accusations of corrupt practices have been levelled at the industry by both the professional and the lay press. The environment is changing, with rising expectations of transparency and ethical standards. In addition, society is becoming increasingly risk averse. There have been examples of poor practice by industry in the past, and industry is learning from these. Equally, there are many examples of excellent practice where industry has worked effectively and ethically with clinicians. The goal of industry is to bring new medicines to benefit patients and shareholders. Commercial success is dependent upon putting the patient at the centre of activity. It also allows re-investment into research and development. This allies industry and healthcare professionals with a common and key ethical arbitrator--the patient. Industry is changing as an acknowledgement of the need to adapt to the culture change demanded by society. Self regulation is increasingly active and transparent; guidelines, laws and internal/external regulators exist to examine industry. However, for the changes in regulations, behaviour and practices to be fully effective, there is a need for dialogue between industry and healthcare professionals. Commitment is needed from both sides to work together to manage the relationship.
GlaxoSmithKline UK Ltd, Building 10, Stockley Park West, Uxbridge, Middlesex UB11 1BT, UK. David.A.Leather@gsk.com
David A
DA
Leather
Sarah C
SC
Davis
D004345:Drug Industry / Q000941:ethics* / Q000331:legislation & jurisprudence; D004992:Ethics, Medical; D004995:Ethics, Professional; D006801:Humans; D007400:Interprofessional Relations; D010372:Pediatrics / Q000941:ethics*; D028743:Professional Misconduct; D018570:Risk Assessment; D012926:Social Control, Formal